Avinash Pandey MD

UCalgary Adult Cardiology | uOttawa Internal Medicine | McMaster MD, Class of 2021

[NEJM Evidence @NEJMEvidence]

Mortality in cardiogenic shock may exceed 50%. In this meta-analysis of 160 studies, Jung et al. identified several modifiable and non-modifiable patient-, presentation-, and procedural-related prognostic factors associated with early mortality. 🔗 https://t.co/lFvNBnA1cq

[FIBA Basketball @FIBA]

They are a PROBLEM. 😈

#Paris2024 x #Basketball

[shireenahmed.bsky.social @_shireenahmed_]

***BREAKING NEWS***

WNBA in The Six is official. Larry Tannenbaum's Kilmer Sports Inc has finalized the deal. What a time for women's sports in Canada!
https://t.co/g5VoesPyy1

[NEJM @NEJM]

Presented at #ACC24:

Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: https://t.co/z1NNeAK9Mm

[Davide Capodanno @DFCapodanno]

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone.

The incidence of a composite of adverse events and a range of adverse outcomes (bleeding, limb ischemia, renal replacement therapy, sepsis) was significantly higher with the use of the microaxial flow pump.

These results of Impella CP are in contrast with those of of IABP in the IABP-SHOCK II trial and venoarterial ECMO in the ECLS-SHOCK trial. Is this because of the device, or because of better patient selection than in prior trials? #ACC24

https://t.co/1VnRl3bdYu

[Dr Pandey Cardiology @Dr_Pandey_Heart]

Congratulations to @AvinashPandeyMD for winning the @SansarFdn #sansarburgundy young investigator award for his research assessing the uptake of #GDMT in #ASCVD in the #southasian population in Canada.

[Pietro Di Santo @PietroDiSantoMD]

@sdparlow presenting the design and rationale of the #DOREMI2 study evaluating inotropes vs. placebo in cardiogenic shock #VASC23

[Emanuele Monda @MondaEmanuele]

Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction

@ESC_Journals @escardio

https://t.co/6iOlb0eqSF

[Deborah Siegal @DebSiegal]

STRATUS Trial published @JAMA_current
🩸Cluster trial 25 ICUs >27,000 patients
🩸Switch to “small-volume” tubes that⬇️blood drawn for lab tests may⬇️RBC transfusion↔️effect on testing
🩸Available, cost-neutral, compatible with analyzers – will you switch?
https://t.co/sTkJVyfrgS

[Ottawa GIM @GIMOttawa]

Congrats to @OttawaIM’s Jun Yi for placing on the podium 2 years in a row!

[American College of Cardiology @ACCinTouch]

✔️ SGLT2 inhibitors have been shown to ↘️ myofilament stiffness & extracellular matrix remodeling/fibrosis in the heart, improving diastolic function.

Read more 🔑 points from a state-of-the-art review on SGLT2 inhibitors in patients w/ #HFpEF: https://t.co/ClP6aAgply #cvPrev

[EHJ Editor-in-Chief @ehj_ed]

The sodium-glucose cotransporter2 inhibitors are robust, disease-modifying therapies in heart failure with preserved ejection fraction. Discover the mechanisms of benefits of #SGLT2 in #HF with preserved EF in #EHJ
https://t.co/WnCblvPH9X
#cardiotwitter @ESC_Journals @escardio

[Henry Han @HanCardiomd]

Mechanisms of benefits of #SGLT2i in #HFpEF and the Multifaceted Benefits of SGLT2i

📌Regulation of blood sugar, blood pressure, and kidney disease progression.
📌Induction of nutrient-deprivation responses leading to increased ketosis and erythropoietin.
📌Improvement in cardiac energetics, function, and iron balance.
📌Reduction of epicardial fat and alteration in adipokine signaling to decrease inflammation.
📌Impact on heart cell ionic balance and reduction of heart tissue stiffness and fibrosis.

@ESC_Journals @DLBHATTMD @SubodhVermaMD

[Avinash Pandey MD @AvinashPandeyMD]

@SubodhVermaMD @oheartcommittee @OttawaIM @CanHFSociety @SCC_CCS

[Avinash Pandey MD @AvinashPandeyMD]

Honored to see our review published in European Heart Journal! In this paper we describe mechanisms of SGLT2i benefit in HFpEF. These medications appear to contribute to improved cardiac energetics.

https://t.co/VFh7uvYbC2

[Shannon Fernando @shanfernands]

🧵Cardiogenic shock after acute MI (AMI-CS) has high in-hospital mortality. But what about long-term outcomes? This matters as much to patients.

Our new @JACCJournals paper (co-led by @Lee_HSterling) looked at long-term outcomes in AMI-CS.

OPEN ACCESS: https://t.co/D1HDT6P4nI

[Shannon Fernando @shanfernands]

This work was led by @Lee_HSterling, with support from @benhibbertMDPhD and @PTanuseputro.

A special thanks to our team of co-investigators: @DQureshi_ @seanvandiepen @susannaprice @efan75 @DiSantoPietro @JungRichardG @sdparlow @Babar_Basir @rebeccamathewmd @thiele_holger

[Lee_Sterling @Lee_HSterling]

Incredible thanks to @shanfernands @benhibbertMDPhD @PTanuseputro @rebeccamathewmd and everyone else on our co-investigator team for all of their support, and expertise to see this project through from start to finish!

[Avinash Pandey MD @AvinashPandeyMD]

@Drhassanmir @OttawaIM @UOHIResearch @SCC_CCS @oheartcommittee

[Avinash Pandey MD @AvinashPandeyMD]

Thrilled to share our paper on a novel app for stratification and optimization of patients with ASCVD - "STOP-CVD". Our app provides personalized recommendations for secondary prevention therapies based on patient risk factors and summarizes the evidence.
https://t.co/wRVLCV8clh